Insilico Medicine launches a deep learned biomarker of aging, Aging.AI 2.0 for testing

(InSilico Medicine, Inc.) Insilico Medicine, Inc., a company applying latest advances in deep learning to biomarker development, drug discovery and aging research, launched Aging.AI 2.0. Comparing Aging.AI 1.0 using 41 blood biochemistry biomarkers, Aging.AI 2.0 uses just 33 parameters from the blood test and has slightly higher mean absolute error.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2fNmlyc